Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas

NCT00153608 is registered in ClinicalTrials.gov with Charite University, Berlin, Germany as lead sponsor.

NCT NCT00153608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00153608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas
Lead sponsor
Charite University, Berlin, Germany
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2004
Completion date
Not reported
Enrollment
25
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

wt1 expressing carcinoma